Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | DRD3 | P35462 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | THPO | P40225 | 1/20 | 0.36 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8475476 | 0.89 | PTGDR2 (0.36) | PTGDR2CYP2D6CYP2C19CYP1A2CYP2C9 | |
| SCHEMBL8473282 | 0.87 | PTGDR2 (0.35) | PTGDR2CYP2D6CYP2C19CYP1A2CYP2C9 | |
| SCHEMBL7914136 | 0.86 | PTGDR2 (0.40) | PTGDR2CYP2D6CYP2C19CYP1A2CYP2C9 | |
| SCHEMBL3365274 | 0.85 | CHRM2 (0.53) | PTGDR2CYP2D6CYP2C19CYP1A2CYP2C9 | |
| SCHEMBL7913181 | 0.84 | ADRA2A (0.43) | PTGDR2CYP2D6CYP2C19CYP1A2CYP2C9 | |
| SCHEMBL8472037 | 0.84 | PTGDR2 (0.39) | PTGDR2NAAATSHR | |
| SCHEMBL8578195 | 0.84 | CYP3A4 (0.43) | PTGDR2CYP2D6CYP2C19CYP1A2CYP2C9 | |
| SCHEMBL290175 | 0.82 | TSHR (0.45) | PTGDR2CYP2D6CYP1A2CYP2C9KCNH2 | |
| SCHEMBL25188997 | 0.81 | SLC6A2 (0.43) | PTGDR2CYP2D6CYP1A2CYP2C9KCNH2 | |
| SCHEMBL11467456 | 0.79 | PTGDR2 (0.43) | PTGDR2SLC6A2SLC6A3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1455776-A4 | A NON-ARRHYTHMOGENIC METABOLITE OF OXYBUTYNIN | BRIDGE PHARMA INC (US) | 2006-05-17 | — | — | EP | claimed |
| EP-1455776-A1 | A NON-ARRHYTHMOGENIC METABOLITE OF OXYBUTYNIN | Bridge Pharma, Inc. (US) | 2004-09-15 | — | — | EP | claimed |
| WO-2003066042-A1 | A NON-ARRHYTHMOGENIC METABOLITE OF OXYBUTYNIN | BRIDGE PHARMA, INC. (US) | 2003-08-14 | — | — | WO | claimed |
| US-6432446-B2 | ADMINISTERING TO A MAMMAL A THERAPEUTICALLY EFFECTIVE AMOUNT OF 4-ETHYLAMINO-2-BUTYNYL CYCLOHEXYL-PHENYLGLYCOLATE AND/ OR ONE OR MORE OPTICALLY ACTIVE ISOMERS, AND SALTS TO TREAT DISORDERS INVOLVING THE URETHROGENITAL TRACT | BRIDGE PHARMA, INC. | 2002-08-13 | — | — | US | claimed |
| US-20020002201-A1 | Non-arrhythmogenic metabolite of oxybutynin | BRIDGE PHARMA, INC. | 2002-01-03 | — | — | US | claimed |
| US-20200276146-A1 | METHODS FOR THE TREATMENT OF SIALORRHEA | NeuRx Pharmaceuticals LLC | 2020-09-03 | — | — | US | disclosed |
| US-10610507-B2 | Methods for the treatment of sialorrhea | NeuRx Pharmaceuticals LLC (US) | 2020-04-07 | — | — | US | disclosed |
| US-20170281585-A1 | METHODS FOR THE TREATMENT OF SIALORRHEA | NeuRx Pharmaceuticals LLC (US) | 2017-10-05 | — | — | US | disclosed |
| US-20160151321-A1 | METHODS FOR THE TREATMENT OF SIALORRHEA | NeuRx Pharmaceuticals LLC | 2016-06-02 | — | — | US | disclosed |
| WO-2014078059-A1 | METHODS FOR THE TREATMENT OF SIALORRHEA | NeuRx Pharmaceuticals LLC (US) | 2014-05-22 | — | — | WO | disclosed |
| US-20140135392-A1 | METHODS FOR THE TREATMENT OF SIALORRHEA | NeuRx Pharmaceuticals LLC (US) | 2014-05-15 | — | — | US | disclosed |
| EP-1286591-B1 | TREATING SMOOTH MUSCLE HYPERACTIVITY WITH (R)-OXYBUTYNIN AND (R)- DESETHYLOXYBUTYNIN | WATSON PHARMACEUTICALS INC (US) | 2010-10-06 | — | — | EP | disclosed |
| EP-1455776-A1 | A NON-ARRHYTHMOGENIC METABOLITE OF OXYBUTYNIN | Bridge Pharma, Inc. (US) | 2004-09-15 | — | — | EP | disclosed |
| WO-2003066042-A1 | A NON-ARRHYTHMOGENIC METABOLITE OF OXYBUTYNIN | BRIDGE PHARMA, INC. (US) | 2003-08-14 | — | — | WO | disclosed |
| EP-1286591-A1 | TREATING SMOOTH MUSCLE HYPERACTIVITY WITH (R)-OXYBUTYNIN AND (R)- DESETHYLOXYBUTYNIN | Watson Pharmaceuticals, Inc. (US) | 2003-03-05 | — | — | EP | disclosed |
| US-6432446-B2 | ADMINISTERING TO A MAMMAL A THERAPEUTICALLY EFFECTIVE AMOUNT OF 4-ETHYLAMINO-2-BUTYNYL CYCLOHEXYL-PHENYLGLYCOLATE AND/ OR ONE OR MORE OPTICALLY ACTIVE ISOMERS, AND SALTS TO TREAT DISORDERS INVOLVING THE URETHROGENITAL TRACT | BRIDGE PHARMA, INC. | 2002-08-13 | — | — | US | disclosed |
| US-20020002201-A1 | Non-arrhythmogenic metabolite of oxybutynin | BRIDGE PHARMA, INC. | 2002-01-03 | — | — | US | disclosed |
| WO-2001093683-A1 | TREATING SMOOTH MUSCLE HYPERACTIVITY WITH (R)-OXYBUTYNIN AND (R)- DESETHYLOXYBUTYNIN | WATSON PHARMACEUTICALS, INC. (US) | 2001-12-13 | — | — | WO | disclosed |
| US-6123961-A | WITHOUT CARDIOVASCULAR DEPRESSING ACTIVITY SIDE EFFECT, BY ADMINISTERING R(-)-4-DIETHYLAMINO-2-BUTYNYL CYCLOHEXYLPHENYLGLYCOLATE OR SALT, FREE OF ITS CORRESPONDING S-ENANTIOMER | BRIDGE PHARMA, INC. (US) | 2000-09-26 | — | — | US | disclosed |
| US-6123961-A | WITHOUT CARDIOVASCULAR DEPRESSING ACTIVITY SIDE EFFECT, BY ADMINISTERING R(-)-4-DIETHYLAMINO-2-BUTYNYL CYCLOHEXYLPHENYLGLYCOLATE OR SALT, FREE OF ITS CORRESPONDING S-ENANTIOMER | BRIDGE PHARMA, INC. (US) | 2000-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002201-A1 | Non-arrhythmogenic metabolite of oxybutynin | TNNT2, TNNC1, CYP11B1 | PTGDR2 1212/4885CYP2D6 44/4885CYP2C19 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.